Author

Katharina Lederer

h-index 9 View on Semantic Scholar

We have 2 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

BACKGROUND Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in a previous phase 2 trial. METHODS We co...

Y. Dauvilliers, Emmanuel Mignot, Jakub Antczak et al. · New England Journal of Medic... · 1 citation

Review Open access Oct 2026

Capturing the Patient Voice: Qualitative Assessment of Daridorexant's Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial.

Patients reported meaningful improvements with daridorexant 50 mg, including better sleep, reduced nocturia, and enhanced physical, cognitive, and emotional functioning, highlighting the value of free‑text surveys for capturing patient‑centered outcomes.

Dario Arnaldi, D. L. Bliwise, Duygu Alpan et al. · Advances in Therapy · 0 citations